Coeptis Therapeutics, Inc.
NASDAQ:COEPBiotechnology
+$0.73 today
- Market cap
- $57.63M
- Beta
- -0.43
- P/E (TTM)
- -8.3
- EPS (TTM)
- -$1.97
Volume 0.18M
Average 0.05M
COEP Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Coeptis Therapeutics, Inc.NASDAQ: COEP
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization grows, but more slowly than its trailing trend
Q1 FY2026 depreciation & amortization of $310.51K rose 1.7% year over year, behind the +12.3% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 1.5% from the prior quarter. Over 3 fiscal years it compounded at +6.9% a year.
Context
- Depreciation & amortization amounted to 89.7% of revenue in FY2025.
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +1.7% toward the trailing-twelve-month pace of +12.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 1.22M USD
- Year-over-year change
- +17.7%
- 4-year CAGR
- +28.6%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.22M | +17.7% |
| FY2024 | 2024-12-31 | 1.04M | +0.3% |
| FY2023 | 2023-12-31 | 1.04M | +3.4% |
| FY2022 | 2022-12-31 | 1M | +123.8% |
| FY2021 | 2021-12-31 | 447.41K | — |
Depreciation & Amortization vs competitors
How COEP compares with its peers on the latest reported figures
- COEP's LTM Mar 2026 depreciation & amortization of $1.23M is the 5th largest of the 9 companies compared; the peer median is $1.43M.
- Its year-over-year change of +12.3% is the 4th highest of 8, against a peer median of +3.7%.
- Depreciation & amortization amounts to 86.8% of revenue for COEP, versus a peer median of 11.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
OSTXOS Therapies Incorporated | LTM Mar 2026 | $363.33M | +106428.1% | +7569.0% | — |
| LTM Mar 2026 | $12.88M | -3.1% | +15.8% | — | |
| LTM Mar 2026 | $2.9M | +21.7% | -19.1% | 8.9% | |
| LTM Mar 2026 | $2.56M | -49.9% | — | 1.7% | |
| LTM Mar 2026 | $1.23M | +12.3% | +6.9% | 86.8% | |
| LTM Mar 2026 | $305K | +6000.0% | +229.4% | 13.3% | |
| LTM Mar 2026 | $119.64K | +3.7% | -17.0% | 35.9% | |
| LTM Mar 2026 | $107K | -22.5% | -0.6% | — | |
| LTM Mar 2026 | $0 | — | — | — | |
| Peer median (excluding COEP) | $1.43M | +3.7% | +7.6% | 11.1% | |
Competitors are the stored peer set for COEP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (13.45M) | (37.57M) | (21.27M) | (10.88M) | (11.92M) |
| Depreciation & Amortization | 447.41K | 1M | 1.04M | 1.04M | 1.22M |
| Deferred Income Tax | 5.34M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.9M | 0 | 477.5K | 1.1M | 1.22M |
| Change in Working Capital | (2.98M) | (550.34K) | 1.73M | (125.26K) | (1.46M) |
| Accounts Receivables | 21.79K | (8.08K) | (30.9K) | (234.74K) | (7.35K) |
| Inventory | (422.02K) | 0 | 0 | 0 | 0 |
| Accounts Payables | (1.58M) | (35.07K) | 1.32M | (149.94K) | (381.01K) |
| Other Working Capital | (1M) | (507.19K) | 437.31K | 259.42K | (1.07M) |
| Other Non-Cash Items | 4.26M | 33.25M | 10.79M | 2.21M | 2.34M |
| Operating Cash Flow | (4.49M) | (3.88M) | (7.24M) | (6.65M) | (8.6M) |
| Capital Expenditures | (1.75M) | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (1.75M) | 0 | 0 | 0 | 0 |
| Debt Repayment | (1.62M) | (2.42M) | (575K) | 1.2M | 771.25K |
| Common Stock Issued | 10.14M | 3.27M | 5.29M | 100K | 12.97M |
| Common Stock Repurchased | (247.17K) | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (50.9K) | 4.63M | 200K | 500K | 0 |
| Financing Cash Flow | 8.22M | 5.49M | 4.92M | 5.71M | 13.74M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 1.98M | 1.61M | (2.32M) | (936.25K) | 5.14M |
| Free Cash Flow | (6.24M) | (3.88M) | (7.24M) | (6.65M) | (8.6M) |
Coeptis Therapeutics, Inc.
NASDAQ:COEP
Intrinsic Alpha fair value
Locked
Current Price
$14.64
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.